Physician profile
Robert W Eitches
NPI 1043256316
$6,885.49
in general payments reported to CMS, 2019-2025
30 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $420 · 2021: $482 · 2022: $1,081 · 2023: $945 · 2024: $884 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,352.97 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,015.90 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $833.15 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $574.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $485.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.68 | 2019-2024 | Spiriva Respimat |
| Amgen INC. | $348.44 | 2022-2025 | Tezspire |
| Optinose US, INC. | $341.74 | 2019-2025 | |
| Kaleo, INC. | $235.06 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $169.14 | 2019-2025 | |
| Ibsa Pharma INC. | $149.26 | 2020-2025 | Licart, Tirosint, Tirosint |
| Teva Pharmaceuticals USA, INC. | $138.69 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $114.43 | 2025 | Neffy |
| Genentech USA, INC. | $108.93 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $99.67 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $74.08 | 2019 | |
| Incyte Corporation | $45.12 | 2023-2024 | Opzelura |
| Abbvie INC. | $39.82 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $38.08 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $34.62 | 2025 | Orladeyo |
| Organon LLC | $29.36 | 2025 | Vtama |
| Cycle Pharmaceuticals INC | $27.07 | 2025 | Sajazir |
| Lilly USA, LLC | $24.41 | 2024 | Zepbound |
| Leo Pharma INC. | $22.79 | 2022 | |
| Mylan Specialty L.P. | $22.64 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.31 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.57 | 2022 | |
| Horizon Therapeutics Plc | $21.10 | 2019 | |
| Circassia INC. | $17.41 | 2019 | |
| Hikma Pharmaceuticals USA | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Eitches listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.